Floatz Rating
CCC55/100
Confidence
Indicative
Sponsor
AstraZeneca
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05775159CT.gov Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer | — | Recruiting | — | — | — |
NCT05489211CT.gov Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) | — | Recruiting | — | — | — |
NCT05123482CT.gov A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Biliary Tract Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Rilvegostomig (this asset) | AstraZeneca | P2 | CCC · 55 |
| Cis-Diamminedichloroplatinum Ii | Merck Sharp & Dohme LLC | P3 | BB |
| Epirubicin | Merck Sharp & Dohme LLC | P3 | BB |
| Pembrolizumab | Merck Sharp & Dohme LLC | P3 | BB |
| Fluorouracilum | Shenzhen Xinhe Biomedical | P2 | B |
| Capecitabine | Zhejiang Cancer Hospital | P2 | B |
| Oxaliplatin | Zhejiang Cancer Hospital | P1/2 | B |
| Datopotamab Deruxtecan | AstraZeneca | P2 | B |
| Durvalumab | Replimune, Inc. | P2 | B |
+42 more in the Biliary Tract Cancer cohort
Other indications for Rilvegostomig
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Non-Small Cell Lung Carcinoma | — | P3 | B · 63 |
| Endometrial Carcinoma | — | P3 | B · 60 |
| Hepatocellular Carcinoma | — | P3 | B · 56 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Rilvegostomig in Biliary Tract Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/rilvegostomig-biliary-tract-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →